<DOC>
	<DOC>NCT00704223</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.</brief_summary>
	<brief_title>Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes HbA1c over 7% No contraindication with NovoMix® 70 Type 1 diabetes Subjects participating in a clinical trial or another observational study Subjects under previous basisbolus insulin therapy Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>